[Soluble heteroprotein conjugates based on recombinant pro-urokinase for ophthalmology].
A procedure is developed for precise synthesis of soluble highly active heteroprotein conjugates enriched in the enzyme with prearranged molecular mass and composition, containing blood serum albumin and recombinant prourokinase. Correlation between the pharmacological activity of the heroconjugates produced and their molecular mass from 2.2 x 10(5) to 5 x 10(5) was studied in experimental vitreous body hemorrhage (hemophthalmia). Heteroconjugates with molecular mass 5 x 10(5) and more exhibited distinctly higher activity due to prolonged fibrinolytic effect. The best medicinal efficiency of the immobilized prourokinase with molecular mass 9 x 10(5) proved to be also in 50-fold decrease of its dose administered into the vitreous body as compared with native enzyme effect.
Kol'tsova
S V
SV
Boĭko
E V
EV
Kuznetsova
N P
NP
Danilichev
V F
VF
D004792:Enzyme Precursors / Q000737:chemistry / Q000627:therapeutic use*; D005130:Eye Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008970:Molecular Weight; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D012709:Serum Albumin / Q000737:chemistry / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000627:therapeutic use*
D004792:Enzyme Precursors; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D012709:Serum Albumin; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase